Protocol Ledger

NCT07449754 · Phase II · RECRUITING

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

Interventional Phase II clinical trial protocol NCT07449754 sponsored by Hanmi Pharmaceutical Company Limited in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-02-12 Enrollment: 45 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07449754
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)45 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07449754
Protocol FieldVerified Registry Value
NCT IdentifierNCT07449754
Consolidated Lead SponsorHanmi Pharmaceutical Company Limited
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment45 participants (ESTIMATED)
Registered Start Date2026-02-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07449754
Hospital Research SiteLocationSite Profile
Seoul National University Bundang HospitalSeongnam-si, South KoreaOpen Hospital Dossier ->
Chonnam National University Hwasun HospitalHwasun, South KoreaOpen Hospital Dossier ->
Kyungpook National University Chilgok HospitalDaegu, South KoreaOpen Hospital Dossier ->
Chungnam National University HospitalDaejeon, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI